Quick answers
- What is Pristiq Extended-Release?
- Pristiq Extended-Release is a brand name of Desvenlafaxine, a prescription medicine. The FDA NDC Directory lists 3 Pristiq Extended-Release products in 3 strengths and forms.
- Who makes Pristiq Extended-Release?
- PF Prism CV holds the FDA application for Pristiq Extended-Release (NDA021992, approved February 29, 2008).
- Is there a generic or store brand of Pristiq Extended-Release?
- Yes. The FDA NDC Directory lists 45 other products with the same active ingredients, strength and form as a Pristiq Extended-Release product, 45 of them generic. Ask your pharmacist whether one is right for you.
- What do pharmacies pay for Pristiq Extended-Release?
- CMS lists a National Average Drug Acquisition Cost (NADAC) for 3 Pristiq Extended-Release strengths and forms (see the table below). That is what pharmacies pay to buy it, not what you pay: your price depends on your insurance and your pharmacy.
- Has Pristiq Extended-Release been recalled?
- FDA enforcement reports list 1 recall of Pristiq Extended-Release products; the newest started April 16, 2014. A recall usually concerns specific lots, not every product.
What Pristiq Extended-Release is
Each Pristiq Extended-Release product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Desvenlafaxine · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| desvenlafaxine succinate 100 mg tablet, extended release (oral) | Pristiq Extended-Release | 14 products, 12 companies | DailyMed |
| desvenlafaxine succinate 25 mg tablet, extended release (oral) | Pristiq Extended-Release | 12 products, 8 companies | DailyMed |
| desvenlafaxine succinate 50 mg tablet, extended release (oral) | Pristiq Extended-Release | 19 products, 14 companies | DailyMed |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Desvenlafaxine →
FDA approval
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| NDA021992 | PF Prism CV | February 29, 2008 | 3 |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| desvenlafaxine succinate 100 mg tablet, extended release | Brand: Pristiq Extended-Release | $13.94 per tablet Generic of the same strength and form: $0.4134 per tablet |
| desvenlafaxine succinate 25 mg tablet, extended release | Brand: Pristiq Extended-Release | $13.97 per tablet Generic of the same strength and form: $0.3870 per tablet |
| desvenlafaxine succinate 50 mg tablet, extended release | Brand: Pristiq Extended-Release | $13.96 per tablet Generic of the same strength and form: $0.3995 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list Pristiq Extended-Release
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Pristiq Extended-Release products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code or label. A recall usually covers specific lots: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
April 16, 2014 · Class II · Terminated · D-1409-2014
Presence of Foreign Tablets/Capsules: Pfizer is recalling 50 mg Pristiq (desvenlafaxine) extended release tablets because a single Pristiq 100 mg tablet was found in a bottle of 50 mg Pristiq.
Pristiq (desvenlafaxine) Extended-Release Tablets 50 mg, 30 count bottle, Rx only, Distributed by Wyeth Pharmaceuticals, Inc., NDC 0008-1211-30 — Pfizer Us Pharmaceutical Group
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.